[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638875":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":55,"collaborators":25,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":25,"eligibilityCriteria":62,"healthyVolunteers":59,"sex":63,"minAge":64,"maxAge":25,"enrollmentInfo":65,"targetDuration":25,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Royal College of Surgeons, Ireland","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Jejunostomy Feeding","ACTIVE_COMPARATOR","Participants randomised to this group will receive standard postoperative enteral nutrition via feeding jejunostomy beginning on postoperative day 1. The standard formula used will be Nutrison Protein Plus 1.25 kcal\u002Fml. Feed initiation and escalation will follow the institution's established enhanced recovery protocol.",[13],"Other: Standard Jejunostomy Feed (Nutrison Protein Plus)",{"label":15,"type":16,"description":17,"interventionNames":18},"Medium-Chain Triglyceride (MCT) Jejunostomy Feeding","EXPERIMENTAL","Participants randomised to this group will receive medium-chain triglyceride (MCT)-based enteral nutrition via feeding jejunostomy beginning on postoperative day 1. The formula used will be Nutrison Peptisorb 1 kcal\u002Fml. Feed initiation and escalation will follow the same protocol as the control group.",[19],"Other: MCT-Based Jejunostomy Feed (Nutrison Peptisorb)",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"Standard Jejunostomy Feed (Nutrison Protein Plus)","Postoperative enteral feeding using a standard long-chain triglyceride-based jejunostomy formula (Nutrison Protein Plus 1.25 kcal\u002Fml), initiated on postoperative day 1 and escalated according to institutional feeding protocol.",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"MCT-Based Jejunostomy Feed (Nutrison Peptisorb)","Postoperative enteral feeding using a medium-chain triglyceride-based jejunostomy formula (Nutrison Peptisorb 1 kcal\u002Fml), initiated on postoperative day 1 and escalated according to institutional feeding protocol.",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Prof jarlath Bolger, MB, BCh, BAO, MCh, FRCSI","CONTACT","018093000","jarbolger@rcsi.com",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Beaumont RCSI Cancer Centre","RECRUITING","Beaumont","Dublin","D09V2N0","Ireland","IE",{"type":46,"coordinates":47},"Point",[48,49],-6.22713,53.38721,{"lat":49,"lon":48},[52],{"name":53,"role":33,"phone":34,"phoneExt":25,"email":54},"Aisling Hegarty, PhD","Aislinghegarty@rcsi.ie",{"type":56,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100638875","mct-enteral-feeding-to-reduce-chyle-leak-after-oesophagectomy-100638875",false,"NCT07616245","MCT Enteral Feeding to Reduce Chyle Leak After Oesophagectomy","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of oesophageal cancer (adenocarcinoma or squamous cell carcinoma)\n* Planned minimally invasive or robotic-assisted oesophagectomy (MIO or RAMIO) with curative intent\n* Placement of feeding jejunostomy at or prior to oesophagectomy\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* No feeding jejunostomy placed at or prior to surgery\n* Prior or concomitant malignancy that would interfere with study protocol or outcomes","ALL","18 Years",{"count":66,"type":67},160,"ESTIMATED","INTERVENTIONAL",[70],"NA","Chyle leak (chylothorax) is a recognised complication following minimally invasive oesophagectomy for oesophageal cancer and may result in prolonged hospital stay, nutritional compromise, and need for additional interventions.\n\nMedium-chain triglyceride (MCT) feeds reduce lymphatic flow as they are absorbed directly via the portal circulation rather than through the thoracic duct. While MCT feeds are commonly used in the management of established chyle leaks, their role in prevention has not been evaluated in a randomised controlled trial.\n\nThis single-centre randomised controlled trial will evaluate whether initiating postoperative jejunostomy feeding with MCT-based enteral nutrition reduces the incidence of clinically and biochemically confirmed chyle leak compared with standard enteral feeding in patients undergoing minimally invasive or robotic-assisted oesophagectomy.\n\nParticipants will be randomised in a 1:1 ratio to receive either MCT-based feeds or standard jejunostomy feeds starting on postoperative day 1. The primary outcome is the incidence of chylothorax. Secondary outcomes include chest drain output, re-intervention rates, and length of hospital stay.",[73],"Oesphageal Cancer",[75,76,77],"Robotic Oesophagectomy","Enhanced Recovery After Surgery","Oesphagectomy","2026-05-29",{"date":80,"type":81},"2026-06-01","ACTUAL",{"date":83,"type":81},"2025-10-02",{"date":85,"type":67},"2028-12-31",{"name":5,"class":6},1]